)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Brii Biosciences (2137) investor relations material
Brii Biosciences H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary21 Aug, 2025
Executive summary
Advanced three fully enrolled Phase 2b HBV clinical studies (ENSURE, ENRICH, ENHANCE), targeting a functional cure for chronic HBV and defining optimal combination regimens.
BREE-179 and BRII-179 showed promising data in enhancing anti-HBs response and accelerating HBsAg loss, supporting shorter PEG-IFNa treatment.
Out-licensed non-core programs, including soralimixin (BRII-693) and Xarelin mixing, in Greater China to focus on HBV and leverage partnerships.
Entered new licensing agreement for psoriatic mixing targeting antimicrobial resistance in Greater China.
Maintained strong cash position, supporting late-stage development and R&D through 2028.
Financial highlights
Cash and cash equivalents as of 06/30/2025 were RMB2,075.3 million, down 14% from RMB2,413.4 million at end of 2024.
Loss for the period narrowed 47.5% year-over-year to RMB148.8 million, mainly due to lower operating expenses and fair value changes in equity investments.
Other income for H1 2025 was RMB28.1 million, a 60.4% decrease year-over-year, mainly due to lower banking interest income and reduced government grants.
R&D expenses for H1 2025 declined 7.3% to RMB117 million, reflecting pipeline prioritization and lower third-party and employee costs.
Administrative expenses dropped 26% to RMB58.2 million, driven by reduced employee, facility, and professional service costs.
Outlook and guidance
Sufficient funds to support operations through 2028.
24-week follow-up data from ENSURE/INSURE cohort 4 expected in H2 2025; end-of-treatment data from ENRICH and ENHANCE studies anticipated in H1 2026.
Unutilized IPO proceeds expected to be used by end of 2027, mainly for HBV, HIV, and MDR/XDR programs.
Ongoing regulatory discussions for Phase 3 study design and endpoints, with focus on biomarker-driven patient enrichment strategies.
Focus remains on advancing HBV cure candidates to registrational studies and seeking partnerships for non-HBV assets.
How will BRII-179 enrichment guide Phase III design?
What is the market impact of shorter PEG interferon?
Future partnership plans for non-core assets?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Brii Biosciences earnings date
H2 202520 Mar, 2026
Next Brii Biosciences earnings date
H2 202520 Mar, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Brii Biosciences Limited is a biotechnology company focused on developing therapies for infectious diseases and central nervous system disorders. The company specializes in innovative treatments for conditions such as hepatitis B, HIV, and drug-resistant bacterial infections. It leverages partnerships with global research institutions and biopharmaceutical firms to advance its pipeline through clinical development and regulatory approval. The company is headquartered in Beijing, China, and its shares are listed on the Hong Kong Stock Exchange (HKEX).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage